Plain-English translation of NCT06687681 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating high-grade brain tumors using active allogeneic natural killer cells — special immune cells from donors that are injected directly into the fluid surrounding your brain. The goal is to see whether these immune cells can help fight the tumor more effectively than standard treatment alone. Natural killer cells are a type of white blood cell that your body normally uses to attack cancer and infected cells.
High-grade brain tumors are aggressive and difficult to treat with surgery, radiation, and chemotherapy alone. Researchers believe that boosting the immune system's ability to fight the tumor directly in the brain — by injecting specialized immune cells — might improve survival and help patients live longer.
You likely qualify if…
You likely don't qualify if…
If you are in the treatment group, you will receive three courses of injections of the immune cells over nine weeks — one injection every three weeks — delivered directly into the fluid around your brain through a lumbar puncture. You will also receive standard brain tumor treatment (surgery, radiation, and/or chemotherapy). If you are in the control group, you will receive only standard treatment. Both groups will be monitored closely with regular visits and imaging scans to see how well the treatment is working.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Iran